ReviewJournal of personalized medicine2023
Personalized Management for Heart Failure with Preserved Ejection Fraction.
Review in Journal of personalized medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Iron Deficiency as a Modifiable Risk Factor in Heart Failure: Evidence and Recommendations.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026Review
- Addressing Unmet Needs in Heart Failure with Preserved Ejection Fraction: Multi-Omics Approaches to Therapeutic Discovery.International journal of molecular sciences · 2026Review
- Targeting Atrial Fibrillation in HFpEF: Comparative Effectiveness of Rhythm Control Strategies and Modulatory Effects of SGLT2 Inhibitors.Journal of clinical medicine · 2025Article
- Machine-Learning-Driven Phenotyping in Heart Failure with Preserved Ejection Fraction: Current Approaches and Future Directions.Medicina (Kaunas, Lithuania) · 2025Review
- A two-phase approach to identifying HFpEF in heart failure patients: Risk score evaluation and decision tree development.ESC heart failure · 2025Article
- Heterogeneity in Heart Failure with Preserved Ejection Fraction: A Systematic Review of Phenotypic Classifications and Clinical Implications.Journal of clinical medicine · 2025Review
- Review
- Obesity-Related Phenotype of Heart Failure With Preserved Ejection Fraction: A Comprehensive Review.Cureus · 2025Review
- 2024 Guidelines of the Taiwan Society of Cardiology for the Diagnosis and Treatment of Heart Failure with Preserved Ejection Fraction.Acta Cardiologica Sinica · 2024Article
- The Therapy and Management of Heart Failure with Preserved Ejection Fraction: New Insights on Treatment.Cardiac failure review · 2024Review
- Phenotype-Specific Outcome and Treatment Response in Heart Failure with Preserved Ejection Fraction with Comorbid Hypertension and Diabetes: A 12-Month Multicentered Prospective Cohort Study.Journal of personalized medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous clinical syndrome with multiple underlying mechanisms and comorbidities that leads to a variety of clinical phenotypes. The identification and characterization of these phenotypes are essential for better understanding the precise pathophysiology of HFpEF, identifying appropriate treatment strategies, and improving patient outcomes. Despite accumulating data showing the potentiality of artificial intelligence (AI)-based phenotyping using clinical, biomarker, and imaging information from multiple dimensions in HFpEF management, contemporary guidelines and consensus do not incorporate these in daily practice. In the future, further studies are required to authenticate and substantiate these findings in order to establish a more standardized approach for clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.